Celltelligence’s Post

View organization page for Celltelligence, graphic

582 followers

#AACR24 Analysis 2: Poseida Therapeutics, Inc., Caribou Biosciences, and Takeda presented clinical and preclinical updates from their programs in hematological malignancies. Celltelligence provides insights and key context for selected presentations. The following topics are covered: • Poseida presented a subanalysis from the Ph1 trial (https://bit.ly/4ac3Ux8) evaluating P-BCMA-#ALLO1 (allogeneic #BCMA CAR-T) including only patients previously treated with BCMA-targeting therapies • Caribou showed CB-012’s (allogeneic CLL-1 CAR-T) preclinical data in #AML supporting IND clearance by the FDA • Takeda presented a new CD123-targeting cell therapy based on vδ1-enriched γδT cells for AML treatment Celltelligence provides insights: https://bit.ly/CT-867124

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics